A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs HDM SPIRE (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Circassia
  • Most Recent Events

    • 09 May 2017 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2017 Top-line results published in a Circassia Media Release.
    • 18 Apr 2017 Primary endpoint has not been met. (Combined score of symptoms and allergy medication)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top